drugset / Trial / NCT07308938

Fluorometholone Study

NCT07308938

Phase 2 Not yet recruiting 174 enrolled Vishal Jhanji University of Pittsburgh Medical Center · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The investigators seek to determine whether adjunctive topical fluorometholone (FML) improves best-corrected visual acuity (BCVA) at 3 months in patients with bacterial corneal ulcers compared with standard topical antibiotic therapy alone.

Timeline

Start
2026-10-31
Primary completion
2029-12-31
Completion
2030-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluorometholone Other / unclassified 0.1 % Topical
Background Cefazolin Small molecule Topical
Background Moxifloxacin Small molecule Topical
Background Tobramycin Small molecule Topical

Indications